BC Innovations | Dec 19, 2019
Distillery Therapeutics

Combined inhibition of EIF4A1 and glutaminase for pancreatic cancer

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inhibiting the translation initiator EIF4A1 and the glutamine metabolism enzyme GLS could treat pancreatic ductal adenocarcinoma (PDAC). An EIF4A1 inhibitor tool compound lowered the viability of mouse PDAC organoids...
BC Innovations | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

Researchers are finding new ways to monitor the immune system in hematologic diseases that could have implications for optimizing immuno-oncology therapies, according to BioCentury’s analysis of emerging targets at ASH 2019. In abstracts released ahead...
BC Extra | Jun 18, 2019
Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
BC Innovations | Apr 10, 2019
Distillery Therapeutics

Diazooxohexanoate-based prodrug of a GLS inhibitor for lymphoma

DISEASE CATEGORY: Cancer INDICATION: Lymphoma Cell culture studies identified a diazooxohexanoate-based prodrug of a GLS inhibitor that could help treat lymphoma. Chemical synthesis and screening of ester prodrugs of the GLS inhibitor 6-diazo-5-oxo-L-norleucine (DON) in...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Innovations | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
BC Innovations | Sep 28, 2018
Targets & Mechanisms

Cell metabolism’s migration

As cancer metabolism undergoes a renaissance in the clinic, with compounds targeting growth factor and nutrient sensing pathways, basic research on metabolic processes in all cells is shining light on pathways that could yield new...
BC Innovations | Sep 20, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting GLS could enhance the efficacy of radiation or reactive oxygen species (ROS)-inducing drugs in IDH1-mutant glioma. In a human glioma cell line expressing mutant IDH1,...
BC Week In Review | Jun 1, 2018
Clinical News

Calithera reports Phase I data for CB-839 combo in solid tumors

Calithera Biosciences Inc. (NASDAQ:CALA) reported data from 16 evaluable patients with advanced solid tumors in the Phase I portion of a Phase I/II trial showing that twice-daily 400-800 mg doses of oral CB-839 plus Xeloda...
BC Innovations | Apr 26, 2018
Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
Items per page:
1 - 10 of 45